Menu

Report content

Flag "SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO"

Help us keep the community safe by telling us why this story should be reviewed.

Article

By omnibakere8
Cancel